Regulation
Drug Decriminalization: What Should Success Look Like?

Key PointsDecriminalization should be judged against harms it can directly reduce rather than…
View more
- Decriminalization should be judged against harms it can directly reduce rather than unrelated supply problems.
- Participants rejected overdose mortality reduction as a realistic primary objective of decriminalization alone.
- Evaluations should track searches and seizures alongside arrests to capture the full enforcement experience.
British Columbia’s drug decriminalization pilot ended on January 31, 2026. The province had removed criminal penalties for certain small-scale possession offences, then substantially narrowed the policy before declining to renew it. In its announcement ending the pilot, the government said the initiative had not delivered the results it hoped for.
That raises a practical question for every jurisdiction considering drug reform: what results should a change in possession law reasonably deliver?
A new study in the International Journal of Drug Policy, “Defining feasible and realistic policy objectives for the decriminalization of personal possession of drugs,” examines that question.1 Its central argument is that governments should judge decriminalization against the harms it can directly reduce, while recognizing which outcomes require additional policies and resources.
For cannabis readers, the value lies in the evaluation framework. The study does not measure cannabis reform. It helps explain why possession laws, regulated supply, policing practices, and health services need separate objectives if policymakers want useful answers about what works.
What Drug Decriminalization Actually Changes
Decriminalization changes the legal consequences of possessing drugs for personal use. It does not automatically create licensed suppliers, introduce product testing, or expand treatment capacity. Those changes require their own rules, budgets, and institutions.
British Columbia’s pilot covered selected substances, including opioids, cocaine, methamphetamine, and MDMA. It was not a cannabis legalization program. The distinction matters because discussions of drug reform often combine very different interventions under one label.
MyCannabis’s updated guide to cannabis legalization and decriminalization makes a related point: permission to possess a substance does not necessarily authorize its cultivation, sale, or public consumption. Each activity can operate under different rules.
The practical consequence is straightforward. If a government changes possession penalties, its most direct opportunity is to change encounters between individuals and the criminal justice system. Expecting that legal amendment alone to solve unrelated supply or service problems risks setting an impossible performance target.
What the Decriminalization Study Found
Researchers conducted 16 interviews in November and December 2021, before British Columbia implemented its pilot. Participants included three law enforcement representatives, three government policymakers, and ten civil society or advocacy representatives. Several also had lived or living experience of substance use.
The interviews explored four proposed objectives and invited participants to identify others. Researchers analyzed recurring themes rather than testing whether the policy subsequently achieved measurable effects.
Participants agreed that reducing criminal justice involvement, personal-possession seizures, and stigma were realistic objectives. However, they attached important conditions to each. Changing legislation could reduce exposure to punishment, but police discretion and institutional practices would influence how much changed in daily life.
| Objective | Participants’ Assessment | Key Qualification |
|---|---|---|
| Reduce criminal justice contact | Realistic, including in the short term | Other offences and discretionary policing can sustain contact |
| Reduce personal-possession seizures | Realistic and central to reducing harms | Depends on limits placed on police seizure powers |
| Reduce stigma | Realistic, often over a longer period | Broader cultural and institutional changes remain necessary |
| Reduce overdose deaths | Not a realistic primary objective on its own | Indirect benefits are possible; toxic supply remains unaddressed |
Participants also discussed health and well-being, racial disparities in enforcement, and justice-system efficiency. These goals generally depended on implementation and complementary changes. Some questioned how much money decriminalization would save where possession charges were already uncommon.
Why Arrest Numbers Tell Only Part of the Story
A decline in arrests can represent meaningful progress. But it does not reveal every interaction that matters to someone carrying drugs.
The study highlights seizures as a separate issue. Participants described how confiscation could encourage people to replace substances quickly, potentially through unfamiliar suppliers or riskier circumstances. Removing the threat of prosecution while retaining disruptive seizure practices could therefore leave important harms intact.
Consider a hypothetical jurisdiction where possession charges fall sharply but searches and confiscations remain common. Its official statistics might show reduced criminalization, while residents still experience frequent enforcement. Neither account necessarily contradicts the other. They measure different parts of the same system.
This suggests a practical improvement for cannabis policy evaluation: distinguish arrests, charges, searches, seizures, and other encounters instead of treating one number as a complete verdict. That is an application of the study’s reasoning, not a cannabis-specific finding.
Distribution matters too. Participants warned that Indigenous people, people living in poverty, and those without stable housing might continue to experience disproportionate enforcement. A province-wide improvement could conceal groups receiving little benefit.
Overdose Outcomes Need Their Own Policy Tools
The paper’s most consequential finding concerns overdose deaths. Participants generally rejected mortality reduction as a realistic primary objective of decriminalization alone, because changing possession penalties does not directly change the contents of an unregulated drug supply.
That does not mean health outcomes are irrelevant. Some participants described possible indirect benefits, including less fear of seeking emergency help, reduced solitary use, and greater comfort accessing services. The distinction is between a plausible pathway and a demonstrated effect.
The BCCDC’s summary of decriminalization evidence illustrates why separate measures matter. It reports that possession offences declined sharply following implementation, while a study of the first 11 months found no statistically significant change in unregulated drug deaths or paramedic-attended opioid overdoses.
Those findings address different questions. They do not make reduced enforcement meaningless, and they do not establish that health benefits followed. A credible evaluation needs room for both conclusions.
Implementation Determines Who Benefits
The policy described in legislation is only part of the intervention. Police need usable guidance. Service providers need staff and capacity. People affected by the rules need to understand where protections apply.
A separate 2026 evaluation update from CIHR reported substantial initial reductions in possession seizures and other criminal justice measures, alongside constraints involving funding, training, and infrastructure. It also emphasized that the May 2024 amendment changed the intervention substantially, complicating evaluation.
This evidence adds operational context to the earlier interviews. It does not convert their expectations into proven causal findings. Instead, it shows why an assessment must specify which version of a policy operated, for how long, and with what support.
The cannabis sector faces a comparable need for precision. MyCannabis’s coverage of Nova Scotia’s cannabis enforcement changes describes a debate about unauthorized sales within a legal market. That concerns supply-chain oversight and enforcement authority, a different question from whether personal possession should attract criminal penalties.
Keeping those questions separate improves accountability. Consumers need clarity about lawful access. Businesses need predictable operating rules. Communities need evidence about safety. None benefits when a single headline statistic substitutes for all three.
Better Measures Can Strengthen Cannabis Policy
The study has clear limits. Its participants were not randomly selected, its sample was small, and its interviews preceded implementation. It captures informed expectations in a particular Canadian setting, not a representative public verdict or a completed evaluation of the pilot.
Its constructive contribution is a better starting point for reform: define the problem, identify the mechanism intended to address it, and choose measures that can reveal whether that mechanism works. Broader health and community outcomes should still be monitored, including unintended harms, without assuming every change has the same cause.
Three developments deserve attention as governments refine drug and cannabis policy:
- Evaluations that track searches and seizures alongside arrests and charges.
- Evidence showing which communities benefit and where unequal enforcement persists.
- Implementation plans that connect legal changes with funded services and clear frontline guidance.
Clearer expectations make reform easier to improve. They allow governments to preserve demonstrated benefits, address implementation failures, and add tools where the original policy cannot do enough. That is a more useful foundation for progress than demanding that one legal change solve every problem surrounding drug use.
References:
1 McAdam, E., Eekhoudt, C. R., Reddon, H., & DeBeck, K. (2026). Defining feasible and realistic policy objectives for the decriminalization of personal possession of drugs. International Journal of Drug Policy, 158, 105598. https://doi.org/10.1016/j.drugpo.2026.105598












